Semi-synthetic vinca alkaloid with an anti-neoplastic activity similar to Vinblastine (see specific info).Indicated for the treatment of certain forms of lung and breast cancer.Routes of administration: intravenous and oral. At latest update relevant published data were not found on excretion into breast milk. In spite of a pharmacokinetic data (large volume of distribution, molecular weight and high binding capacity to blood cells, especially to platelets) that would make it unlikely the passage to milk of significant amounts along with a low bioavailability that would hinder the passage to infant plasma, most experts advise against the use of anti-neoplastic drugs during lactation due to a potential harmful effect on the infant (Pentheroudakis 2010, Koren 2013, pistil 2013, Anderson 2016) until safety data with relation to breastfeeding are provided.It has also been shown that anti-neoplastic drugs may alter the microbial flora balance of breastmilk (Urbaniak 2014). Whenever the option of continuing breastfeeding is preferred, it should be wait for a 5 half-lives period to resume breastfeeding, a period in which 97% of the drug would be eliminated from the body (Anderson 2016).In case of using such a drug it would be wise waiting for 10 days after the last dose to resume breastfeeding. Meanwhile, pump-and-dump regularly to keep production of breastmilk going.